Impact and effectiveness of the quadrivalent human papillomavirus vaccine: A systematic review of 10 years of real-world experience

Prophylactic human papillomavirus (HPV) vaccination programs constitute major public health initiatives worldwide. We assessed the global effect of quadrivalent HPV (4vHPV) vaccination on HPV infection and disease. PubMed and Embase were systematically searched for peer-reviewed articles from Januar...

Full description

Autores:
Tipo de recurso:
Fecha de publicación:
2016
Institución:
Universidad del Rosario
Repositorio:
Repositorio EdocUR - U. Rosario
Idioma:
eng
OAI Identifier:
oai:repository.urosario.edu.co:10336/23687
Acceso en línea:
https://doi.org/10.1093/cid/ciw354
https://repository.urosario.edu.co/handle/10336/23687
Palabra clave:
Wart virus vaccine
Wart virus vaccine
Clinical effectiveness
Condyloma acuminatum
Drug exposure
Embase
Histopathology
Human
Human papillomavirus type 11
Human papillomavirus type 18
Human papillomavirus type 6
Medline
Observational study
Papillomavirus infection
Precancer
Priority journal
Review
Systematic review
Uterine cervix cancer
Uterine cervix cytology
Vaccination
Condyloma acuminatum
Female
Immunology
Male
Papillomaviridae
Papillomavirus infection
Uterine cervix tumor
Vaccination
Virology
Condylomata Acuminata
Female
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
Humans
Male
Papillomaviridae
Papillomavirus Infections
Uterine Cervical Neoplasms
Vaccination
Cervical cancer
CIN
Gardasil/Silgard
Genital warts
HPV vaccination
Rights
License
Abierto (Texto Completo)
Description
Summary:Prophylactic human papillomavirus (HPV) vaccination programs constitute major public health initiatives worldwide. We assessed the global effect of quadrivalent HPV (4vHPV) vaccination on HPV infection and disease. PubMed and Embase were systematically searched for peer-reviewed articles from January 2007 through February 2016 to identify observational studies reporting the impact or effectiveness of 4vHPV vaccination on infection, anogenital warts, and cervical cancer or precancerous lesions. Over the last decade, the impact of HPV vaccination in real-world settings has become increasingly evident, especially among girls vaccinated before HPV exposure in countries with high vaccine uptake. Maximal reductions of approximately 90% for HPV 6/11/16/18 infection, approximately 90% for genital warts, approximately 45% for low-grade cytological cervical abnormalities, and approximately 85% for high-grade histologically proven cervical abnormalities have been reported. The full public health potential of HPV vaccination is not yet realized. HPV-related disease remains a significant source of morbidity and mortality in developing and developed nations, underscoring the need for HPV vaccination programs with high population coverage. © 2016 The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America.